Recent News
Nov 25, 2020

Designation brings PharmaCielo a step closer to EU-GMP compliance; supports continued expansion of medicinal-grade extract exports GACP certification is based on WHO guidelines for quality...

Nov 23, 2020

PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) is pleased to announce the closing of its previously announced private placement of units ("Units") of the Company for...

View more News

View Investor Presentation

If you have any questions please contact

2020 AGM Audio
2020 AGM Audio
CEO Letter to Shareholders February 2020
Q2 2020 Financial Information
Why Invest

We’re a dominant, vertically integrated Colombian cannabis company.

Colombia is one of the few global jurisdictions that have the readily scalable production capacity, expertise and legislative framework to sustainably meet global cannabis demand over the mid- and long-term. The country’s ideal growing environment and decades of experience has made it the foremost supplier of other agricultural commodities including coffee, cut flowers and bananas.

PharmaCielo’s management team and Board of Directors have experience scaling global commodity and consumer goods businesses both within Colombia and around the world. Learn more about our team here.

139 hectares (15 Million square feet) of available cultivation capacity

PharmaCielo received its Colombian manufacturing licence in 2016 and has rapidly become the dominant player in Colombia’s rapidly growing legal cannabis sector. The company is licensed to produce both CBD-dominant and THC-dominant cannabis under quota from the Colombian government. The company was the first Colombian recipient of a licence to cultivate THC-dominant strains and produce THC-focused cannabis oil extracts.

PharmaCielo is on track to rapidly scale its vertically integrated Colombian operations, while continuing to expand operations globally.

Commercial-scale production & sale

The company produces medicinal extracts within its 30,000-sq.-ft. Processing and Extraction Centre (PEC) for which it will be seeking GMP (Good Manufacturing Practices) certification. A variety of extract products are produced from our 30 proprietary government-licensed CBD- and THC-dominant cultivars and shipped to global markets.